Telix Pharmaceuticals Limited’s Price-to-Earnings Ratio at a glance
Telix Pharmaceuticals Limited reports price-to-earnings ratio of 163.3x for Dec 2024. The prior period recorded 617.4x (Dec 2023). Year over year the metric moved −454.12 (−73.6%). The rolling three-period average stands at 253x. Data last refreshed Dec 7, 2025, 2:47 AM.
Latest reading
163.3x · Dec 2024
YoY movement
−454.12 (−73.6%)
Rolling average
253x
Current Price-to-Earnings Ratio
163.3x
−454.12
−73.6%
Rolling average
253x
Latest Value
163.3x
Dec 2024
YoY Change
−454.12
Absolute
YoY Change %
−73.6%
Rate of change
3-Period Avg
253x
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s price-to-earnings ratio stands at 163.3x for Dec 2024. Year-over-year, the metric shifted by −454.12, translating into a −73.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-earnings ratio shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-earnings ratio of 163.3x. Analyze price-to-earnings history, valuation swings, and relative multiples to benchmark market expectations.
Why the P/E ratio matters
The price-to-earnings multiple reveals how much investors are willing to pay for each dollar of net income. Elevated P/E levels suggest strong growth expectations or limited earnings.
Tracking valuation cycles
Monitoring multi-year P/E trends highlights how macro cycles, product launches, or profitability changes impact valuation over time.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s price-to-earnings ratio profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current price-to-earnings ratio?
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-earnings ratio of 163.3x. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's price-to-earnings ratio trending year over year?
Year-over-year, the figure shifts by −454.12 (−73.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does price-to-earnings ratio matter for Telix Pharmaceuticals Limited?
The P/E ratio compares a company’s share price with its per-share earnings to gauge valuation. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's price-to-earnings ratio above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 253x. Comparing the latest reading of 163.3x to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's price-to-earnings ratio refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:47 AM and updates automatically every 24 hours, keeping your valuation inputs current.